Please login to the form below

brodalumab

This page shows the latest brodalumab news and features for those working in and with pharma, biotech and healthcare.

Sun Pharma passes milestone with novel psoriasis drug approval

IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).

Latest news

AbbVie reports more solid data for would-be psoriasis blockbuster

ixekizumab) and Valeant’s Siliq (brodalumab).
Lilly claims another EU okay for Taltz

leader. A third IL-17 drug - Valeant’s Siliq (brodalumab) - was launched in the third quarter in the US at a discount to Cosentyx and Taltz but the company has yet
European Commission backs LEO Pharma’s Kyntheum

Novel biologic therapies such as brodalumab mean that achieving completely clear skin can now be a reality for people with moderate-to-severe psoriasis.”. ... Additionally, across all three trials, 56-61% of patients reported the skin condition no
Biosimilars eat into J&J's Remicade sales

brodalumab) - which claimed an earlier-than-expected FDA approval for psoriasis last week.
Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Meanwhile among other positive opinions granted by the CHMP was one for Leo Pharma's interleukin-17 inhibitor Kyntheum (brodalumab) - acquired from AstraZeneca - for plaque psoriasis.

More from news
Approximately 9 fully matching, plus 34 partially matching documents found.

Latest Intelligence

Pharma deals in September 2015

Brodalumab is phase III complete, but is thought to have been cast off due to concerns raised over links to the drug and suicidal thoughts. ... Collaboration - discovery. 500. AstraZeneca. Valeant Pharmaceuticals. Brodalumab for psoriasis, ready for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Experienced Editor, London, Medical Communications: Competitive package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Editorial Director – Medical Education: Neg

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Senior Medical Writer (Remote Working): Competitive Salary Offered

Director – Head of Public Affairs: Neg

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Account Director – Global Healthcare PR: Salary TBC

Account Director: Negotiable

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Account Director - Digital: Great salary and benefits

Director Healthcare PR Communications: Salary TBC

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Senior Account Executive – Medical Communications: Salary TBC

Associate Medical Director: Highly Competitive

Project / Account Manager (Medical Education): Salary TBC

Scientific Director: Highly Competitive Salary &Benefits

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Account Manager, Healthcare Advertising: Salary TBC

Associate Medical Director: Salary TBC

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Subscribe to our email news alerts

PMHub

Add my company

Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...